News

Filter

Current filters:

axitinib

Pfizer’s axitinib favored by FDA panel

09-12-2011

Global drugs behemoth Pfizer (NYSE: PFE) says that the U.S. Food and Drug Administration’s Oncologic…

axitinibNorth AmericaOncologyPfizerPharmaceuticalRegulation

US FDA accepts Pfizer NDA for kidney cancer drug axitinib

29-06-2011

The US Food and Drug Administration has accepted global drugs behemoth Pfizer’s (NYSE: PFE) filing…

axitinibNorth AmericaOncologyPfizerPharmaceuticalRegulation

Pfizer files for EU approval of axitinib in advanced kidney cancer

02-06-2011

The European Medicines Agency (EMA) has accepted US drugs behemoth Pfizer’s (NYSE: PFE) filing for…

axitinibEuropeOncologyPfizerPharmaceuticalRegulation

Roundup of upcoming cancer drug trials to be presented at ASCO

20-05-2011

A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…

AstraZenecaaxitinibBayerMetMAbNexavarolaparibOncologyPfizerPharmaceuticalResearchRoche

Pfizer commences rolling FDA submission for lung cancer drug crizotinib; denies German VAT evasion

17-01-2011

Global pharma behemoth Pfizer (NYSE: PFE) last week started a rolling submission for a New Drug Application…

axitinibbosutinibcrizotinibEuropeFinancialNorth AmericaOncologyPfizerPharmaceuticalRegulation

COMPANY SPOTLIGHT

Menarini

Back to top